The Safety of Niacin in the US Food and Drug Administration Adverse Event Reporting Database

American Journal of Cardiology

Volumn 101, Issue 8 SUPPL. 1, 2008, Pages

  Alsheikh Ali, Alawi A ^a   Karas, Richard H ^a  

^a Molecular Cardiology Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DATA BASE; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MONOTHERAPY; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SUSTAINED DRUG RELEASE; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG TOXICITY; DYSLIPIDEMIAS; HUMANS; NIACIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41149151640     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.027     Document Type: Article

References (20)

1. Kuvin J.T., Alsheikh-Ali A.A., and Karas R.H. High-density lipoprotein cholesterol-raising strategies. J Cardiovasc Pharmacol 47 (2006) 196-204
2. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164 (2004) 697-705
3. Alsheikh-Ali A., Abourjaily H.M., and Karas R.H. Relative safety of extended-release niacin versus other niacin formulations. [abstract 3754]. Circulation 110 (2004) III-813
4. Alsheikh-Ali A.A., and Karas R.H. Relative safety of lipid altering drugs in the general population. [abstract]. Circulation 112 (2005) II-798
5. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
6. Holoshitz N., Alsheikh-Ali A.A., and Karas R.H. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am J Cardiol 101 (2008) 95-97
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on DetectionEvaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497.
8. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
9. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., Dolor R.J., Ganiats T.G., Gomes A.S., Gornik H.L., Gracia C., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
10. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count?. Atherosclerosis 180 (2005) 217-223
11. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., and Fruchart J.C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
12. Alsheikh-Ali A.A., Lin J.L., Abourjaily P., Ahearn D., Kuvin J.T., and Karas R.H. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 100 (2007) 1499-1501
13. Niaspan [package insert] (2005), Kos Pharmaceuticals, Inc, Cranbury, NJ
14. Zocor [package insert] (2005), Merck & Co, Whitehouse Station, NJ
15. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 suppl (2007) 3C-18C
16. Corsini A., Bellosta S., and Davidson M.H. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 96 suppl (2005) 44K-49K
17. Alsheikh-Ali A.A., and Karas R.H. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration Adverse Event Reporting System). Am J Cardiol 99 (2007) 379-381
18. Begaud B., Martin K., Haramburu F., and Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288 (2002) 1588
19. Rossi A.C., Knapp D.E., Anello C., O'Neill R.T., Graham C.F., Mendelis P.S., and Stanley G.R. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. JAMA 249 (1983) 2226-2228
20. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540